24,000 Registered Attendees Fill the Halls of Successful SPIE Photonics West 2025
10.2.2025 20:55:00 CET | Business Wire | Press release
The largest annual optics and photonics event of the year highlighted exciting new research, networking, and the latest in photonics products and industry trends
SPIE, the international society for optics and photonics, registered 24,000 optics and photonics professionals from over 75countries for Photonics West, as the Society hosted the largest international annual photonics meeting at San Francisco’s Moscone Center. The dynamic week, which ran from 25 to 30 January, featured 1,588 exhibitors and 5,000 technical presentations across four focused tracks – BiOS, LASE, OPTO, Quantum West – four exhibitions, and the co-located AR | VR | MR conference.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250210056991/en/

SPIE Photonics West 2025 exhibition opens for business at San Francisco's Moscone Center. (Photo: Business Wire)
“Photonics West marks the start of the optics and photonics calendar every year,” said SPIE CEO Kent Rochford. “And this year, it also marked a truly exciting milestone for SPIE as the Society’s Membership surpassed 25,000! In addition, our newest conference, Quantum West, continues to grow, reflecting the ongoing development of this exciting technological area and its many applications. Throughout the week, Photonics West 2025 proved to be a terrific meeting of minds, showcasing the varied ways optics and photonics technologies are impacting our lives, and now I’m looking forward to Photonics West 2026, an event which is already in the works.”
As always, the action-filled week showcased the latest innovative technologies and discoveries stemming from a diverse and thriving optics and photonics community, bringing together researchers, innovators, engineers, entrepreneurs, and business leaders from across the globe. More than 100 technical conferences complemented the four exhibitions, bringing researchers and companies together to further science, technology, and applications. The week also included a wide range of live product demonstrations on the exhibition floors as well as a job fair.
The SPIE Industry Program continues to highlight key and critical areas. The SPIE Global Business Forum – which brings together top industry executives for high-level presentations, networking, and conversations – was once again a sold-out success. The glamorous Prism Awards, now in its 17th year, celebrated the best new optics and photonics products, while the inspiring Startup Challenge pitch competition recognized three exciting emerging photonics companies. And at the Quantum West Business Summit, speakers and panelists discussed the current trends in this rapidly growing technical and commercial arena.
In addition, 52 educational courses offered expert-led technical training and learning, complementing the many various professional development and networking opportunities on offer throughout the week: From the Lunchtime Professional Development Education series to social events, Photonics West featured a packed calendar of meet-ups, canine-focused relaxation time, and interactive, collaborative gatherings. And in conjunction with Photonics West, SPIE celebrated 20 years of its Women in Optics notebook, bringing together such luminaries as Ursula Keller, Muyinatu "Bisi" Bell, and Jessica Wade for a day-long event of speakers, panelists, and conversations.
While the week held myriad opportunities for attendees to learn, network, and share their latest advancements, it was the buzzing exhibitions – BiOS Expo, the Photonics West exhibition, the Quantum West Expo, and the AR | VR | MR exhibition – that best showcased the increasingly critical photonics industry and the importance of in-person meetings.
“We started out very fast, very busy right off the jump,” said Optikos Director of Operations Dennis Fantone. “It’s been really exciting connecting with old colleagues and friends that hadn’t been to the show before or hadn’t been in a few years. And this is also a great place to meet up not just with customers but with vendors as well: It’s great to get the personal touch that you just get over email and phone.”
“We’ve had really good traffic and have been able to see old customers and suppliers as well as making new contacts,” said Wasatch Photonics Senior Optical Engineer Elroy Pearson. “Photonics West has been really fruitful.”
“I’ve been going to Photonics West ever since it was a tiny, tiny show in San Jose,” said NKT President and CEO Basil Garabet. “We like this show – for us it’s the big show in the US. And because we are very much into the medical and bio area, being at BiOS as well is good for us. We like the position we’re in on the show floor because we don’t have to move – so that works really well for us: we just set up one booth for both shows. Now we are part of Hamamatsu, and they are right across the way, so again that’s worked out really well for us. It’s altogether good, and we look forward to it when we come over. It’s been a very good week.”
“Photonics West 2025 has highlighted the industry’s strong focus on precision, integration, and scalability in optical and photonic technologies,” noted Dr. Efstratios (Stratos) Kehayas, President, Photonics at G&H. “We’ve seen significant interest in advanced laser beam shaping, integrated photonics for compact systems, and high-reliability optical components for demanding applications in industrial, laser fusion and life sciences. The conversations at our booth reflect a growing demand for solutions that enhance performance while addressing challenges in power efficiency, miniaturization, and system integration.”
During the Photonics West week, SPIE also announced its latest SPIE Endowment Matching Program partnerships, one with Boston University and another with National University of Singapore.
As SPIE Director of Sales Jeff Nichols points out, even after this exciting week, there’s so much to look forward to. “The week of Photonics West has always been the best place to see the size and scope of our industry,” notes Nichols. “And in 2026, we're thrilled to be adding VisionTech, a new exhibit and technical program that will showcase the photonics technologies enabling the imaging and vision markets. With the continued growth of Photonics West, SPIE is turning San Francisco in January into a single stop for anyone interested in the latest advancements in photonics technologies and the numerous applications that they enable.”
SPIE Photonics West 2026 will take place 17-22 January at the Moscone Center in San Francisco. The call for papers for the 2026 event will open in Spring of 2025.
About SPIE
SPIE, the international society for optics and photonics, brings engineers, scientists, students, and business professionals together to advance light-based science and technology. The Society, founded in 1955, connects and engages with our global constituency through industry-leading conferences and exhibitions; publications of conference proceedings, books, and journals in the SPIE Digital Library; and career-building opportunities. Over the past five years, we have invested more than $25 million in the international optics community through our advocacy and support, including scholarships, educational resources, travel grants, endowed gifts, and public-policy development. www.spie.org.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250210056991/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom